In his speech to Congress, President Trump blamed a “slow and burdensome approval process” for holding up medical progress and drug development. We look at whom the president is considering to lead the Food and Drug Administration and how that choice might affect the process of approving drugs for market. Plus, what are the consequences of two of the president’s executive orders - one demanding that two regulations be cut for each new one adopted and another instituting a hiring freeze.
We speak to Dr. Joshua Sharfstein, an Associate Dean at the Johns Hopkins University's Bloomberg School of Public Health. Before he was Maryland’s health secretary, he was the FDA’s Principal Deputy Commissioner.